Smart Inhalers Market - By Product (DPI-based Smart Inhalers, MDI-based Smart Inhalers), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-commerce)– Global Forecast, 2023-2032

Smart Inhalers Market Size

Smart Inhalers Market size was valued at USD 1.5 billion in 2022 and is estimated to account for USD 3.3 billion by 2032. Smart inhalers are sensor-enabled digital devices used for administration of drugs by inhalation as well as monitoring accurate doses and tracking inhaler usage.

Rising prevalence of several chronic respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma is one of the major factors contributing to the market revenue. For instance, as per the European Academy of Allergy and Clinical Immunology (EAACI) in 2022, approximately 350 million people globally are currently suffering from asthma.

The integration of smart inhalers into telemedicine and remote patient monitoring devices, market of which being worth USD 14 billion in 2022, help to enhance patient care and also helps in managing respiratory conditions more effectively. It enables more timely interventions, reduces the need for in-person visits, and allows for a more personalized and patient-centered approach to healthcare. Thus, remotely monitoring and managing patients with respiratory conditions will positively influence the demand for smart inhalers.

COVID-19 Impact

The use of smart inhaler increased significantly during the COVID-19 pandemic. Rise in incidence rate of several respiratory complications among COVID-19 patients propelled the market demand. Moreover, a sudden upsurge in hospital admissions and patient visits associated with breathing problems led to an increased need for effective respiratory care thereby boosting market demand. Therefore, the continued adoption of smart inhalers throughout the pandemic further stimulated the market progress.
 

Smart Inhalers Market Trends

Continuous technological advancements in smart inhalers are projected to accelerate the market growth. As smart inhaler is a part of the new-age digital technology, these devices are being optimized to enhance respiratory ailment management. Enhanced availability of advanced smart inhaler to treat respiratory diseases will fuel the market revenue size.
 

• Advanced devices offer several benefits such as medication history tracker & monitoring, clinical data collection, enhanced accuracy, and ease of use compared to conventional inhalers thereby, accelerating the demand for therapeutic respiratory devices.
  
   
• Furthermore, strong presence of key market players that are proactively involved in innovative product development and launches will fuel industry landscape.
   

Smart Inhalers Market Analysis

The market by product is categorized into on DPI-based smart inhaler and MDI-based smart inhaler. The DPI- based smart inhalers segment garnered USD 959.4 million revenue size in the year 2022.

• DPI-based smart inhaler is used to deliver specific dry powder medication to the lungs. This type of inhaler combines dry powder fluidization mechanism with unique real-time feedback and a data logger for indication of proper inhalation technique.
   
• Moreover, several digital and pharmaceutical companies are focusing on advanced device development mechanisms and integration of add-on sensors thereby resulting in segment expansion.

The smart inhalers market by disease indication is categorized into COPD and asthma. COPD held over 57% of industry share in 2022.

• Growing prevalence of COPD will augment the market demand in upcoming years. Factors such as aging population base, continued exposure to risk factors such as tobacco smoke and air pollution, coupled with improved disease diagnosis contribute to a growing number of COPD patients. Hence, the factors listed above are projected to contribute towards market share.
   
• For instance, as per Forum of International Respiratory Societies (FIRS) survey, COPD is the most prevalent non-communicable respiratory disease. An estimated two hundred million people have COPD and about 3.2 million die each year due to this condition, making it the third-leading cause of death worldwide.
   

The smart inhalers market by distribution channel is categorized into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment accounted for considerable market revenue in 2022 and is estimated to proceed at an 8.3% CAGR during the projected timeframe.

• Expanding infrastructure of hospital pharmacies in emerging markets will proliferate segment expansion. Moreover, easy accessibility to patients seeking treatment from the hospital is another factor contributing to revenue growth.
•  
• Product availability is another factor expected to increase the demand for smart inhalers in these settings. Hospital pharmacies are well connected with the smart inhaler distributors thereby positively influencing overall market trends.

U.S. smart inhalers market accounted for USD 520 million revenue size in 2022 and is predicted to witness substantial market growth over the analysis timeline.

• Technological advancements coupled with substantial healthcare expenditure are the factors driving the market progress. Increasing incidence of chronic respiratory diseases further stimulates the use of smart inhalers.
   
• Major players in the industry are focusing on development of innovative product portfolio for respiratory disease treatment thereby creating new opportunities for the U.S. market size.
   

Smart Inhalers Market Share

The smart inhalers industry is consolidated in nature, with major companies competing to offer superior products in this business space. Prominent players such as Novartis holds a significant share in the market. The companies are diligently directing their efforts towards continuous product innovation and partnership with other players to gain substantial market share. For instance, Novartis collaborated with Propeller Health to connect the digital health platform to enerzair breezhaler in order to treat inadequately controlled asthma patients in Europe.

Some of the eminent market participants operating in the smart inhalers industry include:

• Adherium
• Propeller Health
• Nemera
• GlaxoSmithKline Plc.
• Novartis AG
• Aptar Group Inc
• AstraZeneca Plc
• Findair Sp. Z.o.o.
• BioCorp
• Zeolr Technologies Pvt Ltd.
• Vectura Group Plc.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH

Smart Inhalers Industry News:

• In August 2022, Adherium Limited collaborated with Trudell Medical Limited to offer service to COPD patient in the U.S. This collaboration helped both the companies to strengthen their portfolio.
   
• In February 2022, AstraZeneca announced partnership with Honeywell in order to manufacture advanced respiratory inhalers using propellant HFO-1234ze. Propellant HFO-1234ze has around 99.9% less Global Warming Potential (GWP) as compared to the ones currently used in respiratory medicines. This product launch helped the company to enhance its product offerings in the significant market.
   

Smart inhalers market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product, 2018-2032 (USD Million)

• Dry powder inhaler (DPI)-based smart inhalers
• Metered dose inhaler (MDI)-based smart inhalers

By Disease Indication, 2018-2032 (USD Million)

• Asthma
• Chronic obstructive pulmonary diseases

By Distribution Channel, 2018-2032 (USD Million)

• Hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Turkey
  • Rest of Middle East & Africa